Zynerba Pharmaceuticals (ZYNE) Stock Analysis

What Zynerba Pharmaceuticals does

Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encountered neuropsychiatric conditions. A key product in its pipeline is Zygel, a pharmaceutical-grade cannabidiol expertly crafted into a gel with enhanced skin penetration for topical application. Originally established as AllTranz, Inc., the company adopted its current name, Zynerba Pharmaceuticals, Inc., in August 2014. Founded in 2007, Zynerba Pharmaceuticals maintains its headquarters in Devon, Pennsylvania.

Key metrics

ETFs linked to ZYNE

Broad-market and Healthcare sector ETFs an investor holding Zynerba Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ZYNE fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals trades under the ticker ZYNE on NASDAQ.

Which exchange is ZYNE listed on?

ZYNE is listed on NASDAQ.

What sector does Zynerba Pharmaceuticals operate in?

Zynerba Pharmaceuticals is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).

How can PortView help analyze ZYNE in a portfolio?

PortView shows ZYNE's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.